Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling

Virology

Volumn 436, Issue 1, 2013, Pages 221-234

  Moerdyk Schauwecker, Megan ^a   Shah, Nirav R ^a   Murphy, Andrea M ^a   Hastie, Eric ^a   Mukherjee, Pinku ^a   Grdzelishvili, Valery Z ^a  

^a UNIVERSITY OF NORTH CAROLINA AT CHARLOTTE   (United States)

Author keywords

Anticancer therapy; Cancer; Interferon; MxA; OAS; Oncolytic virus; Resistant cells; Type I interferon; Vesicular stomatitis virus; Virotherapy

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; DOUBLE STRANDED RNA; JANUS KINASE; STAT PROTEIN;

ARTICLE; CANCER CELL; GENE EXPRESSION; HERPES SIMPLEX VIRUS; HUMAN; HUMAN CELL; NONHUMAN; ONCOLYTIC VIROTHERAPY; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; VACCINIA; VESICULAR STOMATITIS VIRUS; VIRUS INFECTIVITY; VIRUS REPLICATION; VIRUS RESISTANCE;

2',5'-OLIGOADENYLATE SYNTHETASE; CELL LINE, TUMOR; GTP-BINDING PROTEINS; HUMANS; INTERFERON TYPE I; JANUS KINASES; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PANCREATIC NEOPLASMS; RHABDOVIRIDAE INFECTIONS; RNA, MESSENGER; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; VESICULAR STOMATITIS; VESICULAR STOMATITIS INDIANA VIRUS; VIRUS REPLICATION;

SIMPLEXVIRUS; VESICULAR STOMATITIS VIRUS;

EID: 84872192098     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2012.11.014     Document Type: Article

References (65)

1. Ahmed M., Cramer S.D., Lyles D.S. Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virology 2004, 330:34-49.
2. Ahmed M., McKenzie M.O., Puckett S., Hojnacki M., Poliquin L., Lyles D.S. Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J. Virol. 2003, 77:4646-4657.
3. Ahmed M., Marino T.R., Puckett S., Kock N.D., Lyles D.S. Immune response in the absence of neurovirulence in mice infected with m protein mutant vesicular stomatitis virus. J. Virol. 2008, 82:9273-9277.
4. Barber G.N. Vesicular stomatitis virus as an oncolytic vector. Viral Immunol. 2004, 17:516-527.
5. Basagoudanavar S.H., Thapa R.J., Nogusa S., Wang J., Beg A.A., Balachandran S. Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses. J. Virol. 2011, 85:2599-2610.
6. Bidwell B.N., Slaney C.Y., Withana N.P., Forster S., Cao Y., Loi S., Andrews D., Mikeska T., Mangan N.E., Samarajiwa S.A., de Weerd N.A., Gould J., Argani P., Moller A., Smyth M.J., Anderson R.L., Hertzog P.J., Parker B.S. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 2012, July 22, [Epub ahead of print].
7. Black B.L., Rhodes R.B., McKenzie M., Lyles D.S. The role of vesicular stomatitis virus matrix protein in inhibition of host-directed gene expression is genetically separable from its function in virus assembly. J. Virol. 1993, 67:4814-4821.
8. Breitbach C.J., Reid T., Burke J., Bell J.C., Kirn D.H. Navigating the clinical development landscape for oncolytic viruses and other cancer therapeutics: no shortcuts on the road to approval. Cytokine Growth Factor Rev. 2010, 21:85-89.
9. Carey B.L., Ahmed M., Puckett S., Lyles D.S. Early steps of the virus replication cycle are inhibited in prostate cancer cells resistant to oncolytic vesicular stomatitis virus. J. Virol. 2008, 82:12104-12115.
10. Cary Z.D., Willingham M.C., Lyles D.S. Oncolytic vesicular stomatitis virus induces apoptosis in U87 Glioblastoma cells by a type II death receptor mechanism and induces cell death and tumor clearance in vivo. J. Virol. 2011, 85:5708-5717.
11. Coulon P., Deutsch V., Lafay F., Martinet-Edelist C., Wyers F., Herman R.C., Flamand A. Genetic evidence for multiple functions of the matrix protein of vesicular stomatitis virus. J. Gen. Virol. 1990, 71:991-996.
12. Donnelly R.P., Kotenko S.V. Interferon-lambda: a new addition to an old family. J. Interferon Cytokine Res. 2010, 30:555-564.
13. Dunn G.P., Sheehan K.C., Old L.J., Schreiber R.D. IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. Cancer Res. 2005, 65:3447-3453.
14. Ebert O., Harbaran S., Shinozaki K., Woo S.L. Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gene Ther. 2005, 12:350-358.
15. Farrow B., Albo D., Berger D.H. The role of the tumor microenvironment in the progression of pancreatic cancer. J. Surg. Res. 2008, 149:319-328.
16. Fuerst T.R., Niles E.G., Studier F.W., Moss B. Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:8122-8126.
17. Furukawa T., Duguid W.P., Rosenberg L., Viallet J., Galloway D.A., Tsao M.S. Long-term culture and immortalization of epithelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am. J. Pathol. 1996, 148:1763-1770.
18. Gaddy D.F., Lyles D.S. Vesicular stomatitis viruses expressing wild-type or mutant M proteins activate apoptosis through distinct pathways. J. Virol. 2005, 79:4170-4179.
19. Gaddy D.F., Lyles D.S. Oncolytic vesicular stomatitis virus induces apoptosis via signaling through PKR, Fas, and Daxx. J. Virol. 2007, 81:2792-2804.
20. Goel A., Carlson S.K., Classic K.L., Greiner S., Naik S., Power A.T., Bell J.C., Russell S.J. Radioiodide imaging and radiovirotherapy of multiple myeloma using VSV(Delta51)-NIS, an attenuated vesicular stomatitis virus encoding the sodium iodide symporter gene. Blood 2007, 110:2342-2350.
21. Haller O., Kochs G. Human MxA protein: an interferon-induced dynamin-like GTPase with broad antiviral activity. J. Interferon Cytokine Res. 2011, 31:79-87.
22. Hamacher R., Schmid R.M., Saur D., Schneider G. Apoptotic pathways in pancreatic ductal adenocarcinoma. Mol. Cancer 2008, 7:64.
23. Hastie E., Grdzelishvili V. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012, Oct. 9, [Epub ahead of print].
24. Honda K., Yanai H., Negishi H., Asagiri M., Sato M., Mizutani T., Shimada N., Ohba Y., Takaoka A., Yoshida N., Taniguchi T. IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 2005, 434:772-777.
25. Iwamura T., Katsuki T.K.I. Establishment and characterization of a human pancreatic cancer cell line (SUIT-2) producing carcinoembryonic antigen and carbohydrate antigen 19-9. Jpn. J. Cancer Res. 1987, 78:54-62.
26. Justesen J., Hartmann R., Kjeldgaard N.O. Gene structure and function of the 2'-5'-oligoadenylate synthetase family. Cell Mol. Life Sci. 2000, 57:1593-1612.
27. Kelly E.J., Nace R., Barber G.N., Russell S.J. Attenuation of vesicular stomatitis virus encephalitis through microRNA targeting. J. Virol. 2010, 84:1550-1562.
28. Le Boeuf F., Diallo J.S., McCart J.A., Thorne S., Falls T., Stanford M., Kanji F., Auer R., Brown C.W., Lichty B.D., Parato K., Atkins H., Kirn D., Bell J.C. Synergistic interaction between oncolytic viruses augments tumor killing. Mol. Ther. 2010, 18:888-895.
29. Lee C.K., Bluyssen H.A., Levy D.E. Regulation of interferon-alpha responsiveness by the duration of Janus kinase activity. J. Biol. Chem. 1997, 272:21872-21877.
30. Lichty B.D., Power A.T., Stojdl D.F., Bell J.C. Vesicular stomatitis virus: re-inventing the bullet. TRENDS in Mol. Med. 2004, 10:210-216.
31. Lindsay T.H., Jonas B.M., Sevcik M.A., Kubota K., Halvorson K.G., Ghilardi J.R., Kuskowski M.A., Stelow E.B., Mukherjee P., Gendler S.J., Wong G.Y., Mantyh P.W. Pancreatic cancer pain and its correlation with changes in tumor vasculature, macrophage infiltration, neuronal innervation, body weight and disease progression. Pain 2005, 119:233-246.
32. Linge C., Gewert D., Rossmann C., Bishop J.A., Crowe J.S. Interferon system defects in human malignant melanoma. Cancer Res. 1995, 55:4099-4104.
33. Mandal S., Abebe F., Chaudhary J. 2'-5'-oligoadenylate synthetase 1 polymorphism is associated with prostate cancer. Cancer 2011, 117:5509-5518.
34. Marozin S., Altomonte J., Stadler F., Thasler W.E., Schmid R.M., Ebert O. Inhibition of the IFN-beta response in hepatocellular carcinoma by alternative spliced isoform of IFN regulatory factor-3. Mol. Ther. 2008, 16:1789-1797.
35. Matin S.F., Rackley R.R., Sadhukhan P.C., Kim M.S., Novick A.C., Bandyopadhyay S.K. Impaired alpha-interferon signaling in transitional cell carcinoma: lack of p48 expression in 5637 cells. Cancer Res. 2001, 61:2261-2266.
36. Monsurro V., Beghelli S., Wang R., Barbi S., Coin S., Di Pasquale G., Bersani S., Castellucci M., Sorio C., Eleuteri S., Worschech A., Chiorini J.A., Pederzoli P., Alter H., Marincola F.M., Scarpa A. Anti-viral state segregates two molecular phenotypes of pancreatic adenocarcinoma: potential relevance for adenoviral gene therapy. J. Transl. Med. 2010, 8:10.
37. Moyer S.A., Baker S.C., Lessard J.L. Tubulin: a factor necessary for the synthesis of both Sendai virus and vesicular stomatitis virus RNAs. Proc. Natl. Acad. Sci. U.S.A. 1986, 83:5405-5409.
38. Murphy A.M., Besmer D.M., Moerdyk-Schauwecker M., Moestl N., Ornelles D.A., Mukherjee P., Grdzelishvili V.Z. Vesicular stomatitis virus as an oncolytic agent against pancreatic ductal adenocarcinoma. J. Virol. 2012, 86:3073-3087.
39. Naik S., Russell S.J. Engineering oncolytic viruses to exploit tumor specific defects in innate immune signaling pathways. Expert Opin. Biol. Ther. 2009, 9:1163-1176.
40. Nakhaei P., Genin P., Civas A., Hiscott J. RIG-I-like receptors: sensing and responding to RNA virus infection. Semin. Immunol. 2009, 21:215-222.
41. Okabe T., Yamaguchi N., Ohsawa N. Establishment and characterization of a carcinoembryonic antigen (CEA)-producing cell line from a human carcinoma of the exocrine pancreas. Cancer 1983, 51:662-668.
42. Ottolino-Perry K., Diallo J.S., Lichty B.D., Bell J.C., McCart J.A. Intelligent design: combination therapy with oncolytic viruses. Mol. Ther. 2010, 18:251-263.
43. Paglino J.C., van den Pol A.N. Vesicular stomatitis virus has extensive oncolytic activity against human sarcomas: rare resistance is overcome by blocking interferon pathways. J. Virol. 2011, 85:9346-9358.
44. Paladino P., Mossman K.L. Mechanisms employed by herpes simplex virus 1 to inhibit the interferon response. J. Interferon. Cytokine Res. 2009, 29:599-607.
45. Perdiguero B., Esteban M. The interferon system and vaccinia virus evasion mechanisms. J. Interferon Cytokine Res. 2009, 29:581-598.
46. Pfeffer L.M., Wang C., Constantinescu S.N., Croze E., Blatt L.M., Albino A.P., Nanus D.M. Human renal cancers resistant to IFN's antiproliferative action exhibit sensitivity to IFN's gene-inducing and antiviral actions. J. Urol. 1996, 156:1867-1871.
47. Roy L.D., Sahraei M., Subramani D.B., Besmer D., Nath S., Tinder T.L., Bajaj E., Shanmugam K., Lee Y.Y., Hwang S.I., Gendler S.J., Mukherjee P. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011, 30:1449-1459.
48. Russell S.J., Peng K.W. Viruses as anticancer drugs. Trends Pharmacol. Sci. 2007, 28:326-333.
49. Sadler A.J., Williams B.R. Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 2008, 8:559-568.
50. Saloura V., Wang L.C., Fridlender Z.G., Sun J., Cheng G., Kapoor V., Sterman D.H., Harty R.N., Okumura A., Barber G.N., Vile R.G., Federspiel M.J., Russell S.J., Litzky L., Albelda S.M. Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy. Hum. Gene Ther. 2010, 21:51-64.
51. Schuster A., Johnston I.C., Das T., Banerjee A.K., Pavlovic J., ter M.V., Schneider-Schaulies S. Expression of the human MxA protein is associated with hyperphosphorylation of VSV P protein in human neural cells. Virology 1996, 220:241-245.
52. Sharif-Askari E., Nakhaei P., Oliere S., Tumilasci V., Hernandez E., Wilkinson P., Lin R., Bell J., Hiscott J. Bax-dependent mitochondrial membrane permeabilization enhances IRF3-mediated innate immune response during VSV infection. Virology 2007, 365:20-33.
53. Shmulevitz M., Pan L.Z., Garant K., Pan D., Lee P.W. Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res. 2010, 70:4912-4921.
54. Stathis A., Moore M.J. Advanced pancreatic carcinoma: current treatment and future challenges. Nat. Rev. Clin. Oncol. 2010, 7:163-172.
55. Stojdl D.F.L.B., tenOever B.R., Paterson J.M., Power A.T., Knowles S., Marius R., Reynard J., Poliquin L., Atkins H., Brown E.G., Durbin R.K., Durbin J.E., Hiscott J., Bell J.C. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2003, 4:263-275.
56. Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000, 6:821-825.
57. Sun W.H., Pabon C., Alsayed Y., Huang P.P., Jandeska S., Uddin S., Platanias L.C., Rosen S.T. Interferon-alpha resistance in a cutaneous T-cell lymphoma cell line is associated with lack of STAT1 expression. Blood 1998, 91:570-576.
58. Vähä-Koskela M.J., Heikkilä J.E., Hinkkanen A.E. Oncolytic viruses in cancer therapy. Cancer Lett. 2007, 254:178-216.
59. Wang B.X., Rahbar R., Fish E.N. Interferon: current status and future prospects in cancer therapy. J. Interferon Cytokine Res. 2011, 31:545-552.
60. Wilden H., Fournier P., Zawatzky R., Schirrmacher V. Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle disease virus. Int. J. Oncol. 2009, 34:971-982.
61. Wollmann G., Rogulin V., Simon I., Rose J.K., van den A.N. Some attenuated variants of vesicular stomatitis virus show enhanced oncolytic activity against human glioblastoma cells relative to normal brain cells. J. Virol. 2010, 84:1563-1573.
62. Wong L.H., Krauer K.G., Hatzinisiriou I., Estcourt M.J., Hersey P., Tam N.D., Edmondson S., Devenish R.J., Ralph S.J. Interferon-resistant human melanoma cells are deficient in ISGF3 components, STAT1, STAT2, and p48-ISGF3gamma. J. Biol. Chem. 1997, 272:28779-28785.
63. Wongthida P., Diaz R.M., Galivo F., Kottke T., Thompson J., Melcher A., Vile R. VSV oncolytic virotherapy in the B16 model depends upon intact MyD88 signaling. Mol. Ther. 2011, 19:150-158.
64. Wu L., Huang T.G., Meseck M., Altomonte J., Ebert O., Shinozaki K., García-Sastre A., Fallon J., Mandeli J., Woo S.L. rVSV(M Delta 51)-M3 is an effective and safe oncolytic virus for cancer therapy. Hum. Gene Ther. 2008, 19:635-647.
65. Zhang K.X., Matsui Y., Hadaschik B.A., Lee C., Jia W., Bell J.C., Fazli L., So A.I., Rennie P.S. Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death. Int. J. Cancer 2010, 127:830-838.